Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer
1992

Prolactin Levels in Breast Cancer Patients

Sample size: 73 publication Evidence: moderate

Author Information

Author(s): P.R. Maddox, D.L. Jones, R.E. Mansel

Primary Institution: University Department of Surgery, University of Wales College of Medicine

Hypothesis

Are basal prolactin and total lactogenic hormone levels elevated in breast cancer patients compared to controls?

Conclusion

Breast cancer patients have significantly elevated levels of bioactive prolactin compared to age-matched controls.

Supporting Evidence

  • Bioactive prolactin levels were significantly elevated in breast cancer patients compared to controls.
  • 61% of breast cancer patients had elevated BA IRMA prolactin ratios above the upper limit of normal.
  • The study used both a new microbioassay and conventional immunoassay to measure hormone levels.

Takeaway

This study found that women with breast cancer have higher levels of a hormone called prolactin compared to women without breast cancer.

Methodology

The study measured prolactin and total lactogenic hormone levels in 33 breast cancer patients and 40 age-matched controls using a microbioassay and immunoassay.

Limitations

The study excluded patients with endocrinological disorders and those on certain medications, which may limit generalizability.

Participant Demographics

33 breast cancer patients and 40 age-matched normal female volunteers, with a majority being postmenopausal.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication